Drug discovery in focal and segmental glomerulosclerosis

Kidney International

Volumn 89, Issue 6, 2016, Pages 1211-1220

  Pullen, Nick ^a   Fornoni, Alessia ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

focal segmental glomerulosclerosis; podocyte; proteinuria

Indexed keywords

DRUG RESEARCH; DRUG TARGETING; EVIDENCE BASED MEDICINE; EXPERIMENTAL STUDY; FOCAL GLOMERULOSCLEROSIS; GENETIC ASSOCIATION; GENETIC TRAIT; HUMAN; NONHUMAN; PATIENT CARE; PODOCYTE; PRIORITY JOURNAL; REPLICATION STUDY; REVIEW; TRANSLATIONAL RESEARCH; VALIDATION PROCESS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; GENETICS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLOMERULUS; GLOMERULUS FILTRATION RATE; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PHENOTYPE; PROTEINURIA; TRENDS;

AARF DOMAIN CONTAINING KINASE 4, HUMAN; PROTEIN KINASE;

CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY GLOMERULUS; MOLECULAR TARGETED THERAPY; MUTATION; PHENOTYPE; PODOCYTES; PROTEIN KINASES; PROTEINURIA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84978120358     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2015.12.058     Document Type: Review

References (120)

1. 1 US Renal Data System. 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. 2011. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
2. 2 D'Agati, V.D., Kaskel, F.J., Falk, R.J., Focal segmental glomerulosclerosis. N Engl J Med 365 (2011), 2398–2411.
3. 3 Murray, C.J., Lopez, A.D., Measuring the global burden of disease. N Engl J Med 369 (2013), 448–457.
4. 4 Coresh, J., Turin, T.C., Matsushita, K., et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311 (2014), 2518–2531.
5. 5 Inker, L.A., Levey, A.S., Pandya, K., et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64 (2014), 74–85.
6. 6 Thompson, A., Cattran, D.C., Blank, M., et al. Complete and partial remission as surrogate end points in membranous nephropathy. J Am Soc Nephrol 26 (2015), 2930–2937.
7. 7 Wickman, L., Afshinnia, F., Wang, S.Q., et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol 24 (2013), 2081–2095.
8. 8 Palmer, S.C., Sciancalepore, M., Strippoli, G.F., Trial quality in nephrology: how are we measuring up?. Am J Kidney Dis 58 (2011), 335–337.
9. 9 Somlo, S., Mundel, P., Getting a foothold in nephrotic syndrome. Nat Genet 24 (2000), 333–335.
10. 10 Ruotsalainen, V., Ljungberg, P., Wartiovaara, J., et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A 96 (1999), 7962–7967.
11. 11 Tryggvason, K., Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10 (1999), 2440–2445.
12. 12 Kerjaschki, D., Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 108 (2001), 1583–1587.
13. 13 Asanuma, K., Mundel, P., The role of podocytes in glomerular pathobiology. Clin Exp Nephrol 7 (2003), 255–259.
14. 14 Boerries, M., Grahammer, F., Eiselein, S., et al. Molecular fingerprinting of the podocyte reveals novel gene and protein regulatory networks. Kidney Int 83 (2013), 1052–1064.
15. 15 Grgic, I., Hofmeister, A.F., Genovese, G., et al. Discovery of new glomerular disease-relevant genes by translational profiling of podocytes in vivo. Kidney Int 86 (2014), 1116–1129.
16. 16 Mathieson, P.W., The podocyte as a target for therapies—new and old. Nat Rev Nephrol 8 (2012), 52–56.
17. 17 Arif, E., Nihalani, D., Podocytes as a therapeutic target. Ann Clin Exp Hypertens 1 (2013), 1003–1013.
18. 18 Cook, D., Brown, D., Alexander, R., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13 (2014), 419–431.
19. 19 Nelson, M.R., Tipney, H., Painter, J.L., et al. The support of human genetic evidence for approved drug indications. Nat Genet 47 (2015), 856–860.
20. 20 Plenge, R.M., Scolnick, E.M., Altshuler, D., Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12 (2013), 581–594.
21. 21 Reiser, J., Polu, K.R., Moller, C.C., et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37 (2005), 739–744.
22. 22 Winn, M.P., Conlon, P.J., Lynn, K.L., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308 (2005), 1801–1804.
23. 23 Moller, C.C., Wei, C., Altintas, M.M., et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18 (2007), 29–36.
24. 24 Hauser, P.V., Pippin, J.W., Kaiser, C., et al. Novel siRNA delivery system to target podocytes in vivo. PLoS One, 5, 2010, e9463.
25. 25 Wang, L., Jirka, G., Rosenberg, P.B., et al. Gq signaling causes glomerular injury by activating TRPC6. J Clin Invest 125 (2015), 1913–1926.
26. 26 Schaldecker, T., Kim, S., Tarabanis, C., et al. Inhibition of the TRPC5 ion channel protects the kidney filter. J Clin Invest 123 (2013), 5298–5309.
27. 27 Miller, M., Shi, J., Zhu, Y., et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem 286 (2011), 33436–33446.
28. 28 Martini, S., Nair, V., Keller, B.J., et al. Integrative biology identifies shared transcriptional networks in CKD. J Am Soc Nephrol 25 (2014), 2559–2572.
29. 29 Kretzler, M., Sedor, J.R., Introduction: precision medicine for glomerular disease: the road forward. Semin Nephrol 35 (2015), 209–211.
30. 30 Ashraf, S., Gee, H.Y., Woerner, S., et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 123 (2013), 5179–5189.
31. 31 Hodgin, J.B., Bitzer, M., Wickman, L., et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J Am Soc Nephrol 26 (2015), 3162–3178.
32. 32 Peired, A., Lazzeri, E., Lasagni, L., et al. Glomerular regeneration: when can the kidney regenerate from injury and what turns failure into success?. Nephron Exp Nephrol, 126, 2014, 70.
33. 33 Fukuda, A., Wickman, L.T., Venkatareddy, M.P., et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 81 (2012), 40–55.
34. 34 Saleem, M.A., O'Hare, M.J., Reiser, J., et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13 (2002), 630–638.
35. 35 Ni, L., Saleem, M., Mathieson, P.W., Podocyte culture: tricks of the trade. Nephrology 17 (2012), 525–531.
36. 36 Da Sacco, S., Lemley, K.V., Sedrakyan, S., et al. A novel source of cultured podocytes. PLoS One, 8, 2013, e81812.
37. 37 Song, B., Smink, A.M., Jones, C.V., et al. The directed differentiation of human iPS cells into kidney podocytes. PLoS One, 7, 2012, e46453.
38. 38 Fornoni, A., Sageshima, J., Wei, C., et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med, 3, 2011, 85ra46.
39. 39 Merscher-Gomez, S., Guzman, J., Pedigo, C.E., et al. Cyclodextrin protects podocytes in diabetic kidney disease. Diabetes 62 (2013), 3817–3827.
40. 40 Lee, H.W., Khan, S.Q., Faridi, M.H., et al. A podocyte-based automated screening assay identifies protective small molecules. J Am Soc Nephrol 26 (2015), 2741–2752.
41. 41 Peti-Peterdi, J., Kidokoro, K., Riquier-Brison, A., Novel in vivo techniques to visualize kidney anatomy and function. Kidney Int 88 (2015), 44–51.
42. 42 Schiffer, M., Teng, B., Gu, C., et al. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. Nat Med 21 (2015), 601–609.
43. 43 Yaddanapudi, S., Altintas, M.M., Kistler, A.D., et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest 121 (2011), 3965–3980.
44. 44 Harris, J.J., McCarthy, H.J., Ni, L., et al. Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1. J Pathol 229 (2013), 660–671.
45. 45 Anderson, M., Kim, E.Y., Hagmann, H., et al. Opposing effects of podocin on the gating of podocyte TRPC6 channels evoked by membrane stretch or diacylglycerol. Am J Physiol Cell Physiol 305 (2013), C276–C289.
46. 46 Ito, T., Ando, H., Suzuki, T., et al. Identification of a primary target of thalidomide teratogenicity. Science 327 (2010), 1345–1350.
47. 47 Jang, K.J., Mehr, A.P., Hamilton, G.A., et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol (Camb) 5 (2013), 1119–1129.
48. 48 Huh, D., Leslie, D.C., Matthews, B.D., et al. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Transl Med, 4, 2012, 159ra147.
49. 49 Savin, V.J., Sharma, R., Sharma, M., et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 334 (1996), 878–883.
50. 50 Sugano, Y., Lindenmeyer, M.T., Auberger, I., et al. The Rho-GTPase binding protein IQGAP2 is required for the glomerular filtration barrier. Kidney Int 88 (2015), 1047–1056.
51. 51 Pullen, N., Birch, C.L., Douglas, G.J., et al. The translational challenge in the development of new and effective therapies for endometriosis: a review of confidence from published preclinical efficacy studies. Hum Reprod Update 17 (2011), 791–802.
52. 52 Prinz, F., Schlange, T., Asadullah, K., Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov, 10, 2011, 712.
53. 53 Begley, C.G., Ellis, L.M., Drug development: raise standards for preclinical cancer research. Nature 483 (2012), 531–533.
54. 54 Spinale, J.M., Mariani, L.H., Kapoor, S., et al. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87 (2015), 564–574.
55. 55 Leeson, P.D., Springthorpe, B., The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6 (2007), 881–890.
56. 56 Morgan, P., Van Der Graaf, P.H., Arrowsmith, J., et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov Today 17 (2012), 419–424.
57. 57 Barton, M., Sorokin, A., Endothelin and the glomerulus in chronic kidney disease. Semin Nephrol 35 (2015), 156–167.
58. 58 Bu, X., Zhou, Y., Zhang, H., et al. Systemic administration of naked plasmid encoding HGF attenuates puromycin aminonucleoside-induced damage of murine glomerular podocytes. Am J Physiol Renal Physiol 301 (2011), F784–F792.
59. 59 Buelli, S., Rosano, L., Gagliardini, E., et al. β-Arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol 25 (2014), 523–533.
60. 60 Ju, W., Nair, V., Smith, S., et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med, 7, 2015, 316ra193.
61. 61 Lai, J.Y., Luo, J., O'Connor, C., et al. MicroRNA-21 in glomerular injury. J Am Soc Nephrol 26 (2015), 805–816.
62. 62 Lin, C.L., Lee, P.H., Hsu, Y.C., et al. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J Am Soc Nephrol 25 (2014), 1698–1709.
63. 63 Takagi, N., Tanizawa, T., Kon, V., et al. Mineralocorticoid receptor blocker protects against podocyte-dependent glomerulosclerosis. Nephron Extra 2 (2012), 17–26.
64. 64 Helmering, J., Juan, T., Li, C.M., et al. A mutation in Ampd2 is associated with nephrotic syndrome and hypercholesterolemia in mice. Lipids Health Dis, 13, 2014, 167.
65. 65 Wei, C., Moller, C.C., Altintas, M.M., et al. Modification of kidney barrier function by the urokinase receptor. Nat Med 14 (2008), 55–63.
66. 66 Yu, C.C., Fornoni, A., Weins, A., et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 369 (2013), 2416–2423.
67. 67 Borza, C.M., Su, Y., Chen, X., et al. Inhibition of integrin alpha2beta1 ameliorates glomerular injury. J Am Soc Nephrol 23 (2012), 1027–1038.
68. 68 Pereira, R.L., Buscariollo, B.N., Correa-Costa, M., et al. Bradykinin receptor 1 activation exacerbates experimental focal and segmental glomerulosclerosis. Kidney Int 79 (2011), 1217–1227.
69. 69 Oh, J., Beckmann, J., Bloch, J., et al. Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int 80 (2011), 483–492.
70. 70 George, B., Verma, R., Soofi, A.A., et al. Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest 122 (2012), 674–692.
71. 71 Gu, L., Liang, X., Wang, L., et al. Functional metabotropic glutamate receptors 1 and 5 are expressed in murine podocytes. Kidney Int 81 (2012), 458–468.
72. 72 Giardino, L., Armelloni, S., Corbelli, A., et al. Podocyte glutamatergic signaling contributes to the function of the glomerular filtration barrier. J Am Soc Nephrol 20 (2009), 1929–1940.
73. 73 Tamura, Y., Tanabe, K., Kitagawa, W., et al. Nicorandil, a K(atp) channel opener, alleviates chronic renal injury by targeting podocytes and macrophages. Am J Physiol Renal Physiol 303 (2012), F339–F349.
74. 74 Wu, J., Zheng, C., Wang, X., et al. MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytes. J Clin Invest 125 (2015), 4091–4106.
75. 75 Djudjaj S, Lue H, Rong S, et al. Macrophage migration inhibitory factor mediates proliferative GN via CD74 [e-pub ahead of print]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2015020149, accessed April 18, 2016.
76. 76 Hall, G., Rowell, J., Farinelli, F., et al. Phosphodiesterase 5 inhibition ameliorates angiotensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. Am J Physiol Renal Physiol 306 (2014), F1442–F1450.
77. 77 Ravani, P., Ponticelli, A., Siciliano, C., et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84 (2013), 1025–1033.
78. 78 Nijenhuis, T., Sloan, A.J., Hoenderop, J.G., et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 179 (2011), 1719–1732.
79. 79 Heeringa, S.F., Chernin, G., Chaki, M., et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 121 (2011), 2013–2024.
80. 80 Gee, H.Y., Saisawat, P., Ashraf, S., et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 123 (2013), 3243–3253.
81. 81 Faul, C., Donnelly, M., Merscher-Gomez, S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14 (2008), 931–938.
82. 82 Clement, L.C., Mace, C., Avila-Casado, C., et al. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 20 (2014), 37–46.
83. 83 Jo, S.K., Bajwa, A., Awad, A.S., et al. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int 73 (2008), 1220–1230.
84. 84 Janiak, P., Poirier, B., Bidouard, J.P., et al. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int 72 (2007), 1345–1357.
85. 85 Joy, M.S., Gipson, D.S., Powell, L., et al. Phase 1 trial of adalimumab in focal segmental glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 55 (2010), 50–60.
86. 86 McCarthy, E.T., Sharma, M., Savin, V.J., Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5 (2010), 2115–2121.
87. 87 Sampson, M.G., Robertson, C.C., Martini, S., et al. Integrative genomics identifies novel associations with APOL1 risk genotypes in black NEPTUNE subjects. J Am Soc Nephrol 27 (2015), 814–823.
88. 88 Yokoi, H., Mukoyama, M., Mori, K., et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 73 (2008), 446–455.
89. 89 Ijaz, A., Tejada, T., Catanuto, P., et al. Inhibition of C-jun N-terminal kinase improves insulin sensitivity but worsens albuminuria in experimental diabetes. Kidney Int 75 (2009), 381–388.
90. 90 Gorin, Y., Cavaglieri, R.C., Khazim, K., et al. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes. Am J Physiol Renal Physiol 308 (2015), F1276–F1287.
91. 91 Menne, J., Shushakova, N., Bartels, J., et al. Dual inhibition of classical protein kinase C-alpha and protein kinase C-beta isoforms protects against experimental murine diabetic nephropathy. Diabetes 62 (2013), 1167–1174.
92. 92 Tossidou, I., Teng, B., Menne, J., et al. Podocytic PKC-alpha is regulated in murine and human diabetes and mediates nephrin endocytosis. PLoS One, 5, 2010, e10185.
93. 93 Trachtman, H., Fervenza, F.C., Gipson, D.S., et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 79 (2011), 1236–1243.
94. 94 van Roeyen, C.R., Eitner, F., Boor, P., et al. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 80 (2011), 1292–1305.
95. 95 Wang, Y., Deb, D.K., Zhang, Z., et al. Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol 23 (2012), 1977–1986.
96. 96 Pengal, R., Guess, A.J., Agrawal, S., et al. Inhibition of the protein kinase MK-2 protects podocytes from nephrotic syndrome-related injury. Am J Physiol Renal Physiol 301 (2011), F509–F519.
97. 97 Saurus, P., Kuusela, S., Lehtonen, E., et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. Cell Death Dis, 6, 2015, e1752.
98. 98 Stitt-Cavanagh, E.M., Faour, W.H., Takami, K., et al. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 21 (2010), 1678–1690.
99. 99 Yamada, S., Nakamura, J., Asada, M., et al. Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. PLoS One, 9, 2014, e89135.
100. 100 Yoshida, S., Nagase, M., Shibata, S., et al. Podocyte injury induced by albumin overload in vivo and in vitro: involvement of TGF-beta and p38 MAPK. Nephron Exp Nephrol 108 (2008), e57–e68.
101. 101 Agrawal, S., Guess, A.J., Chanley, M.A., et al. Albumin-induced podocyte injury and protection are associated with regulation of COX-2. Kidney Int 86 (2014), 1150–1160.
102. 102 Brosius, F.C. 3rd, He, J.C., JAK inhibition and progressive kidney disease. Curr Opin Nephrol Hypertens 24 (2015), 88–95.
103. 103 Miyazaki, Y., Shimizu, A., Pastan, I., et al. Keap1 inhibition attenuates glomerulosclerosis. Nephrol Dial Transplant 29 (2014), 783–791.
104. 104 Zhou, L.L., Cao, W., Xie, C., et al. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int 82 (2012), 759–770.
105. 105 Lal, M.A., Andersson, A.C., Katayama, K., et al. Rhophilin-1 is a key regulator of the podocyte cytoskeleton and is essential for glomerular filtration. J Am Soc Nephrol 26 (2015), 647–662.
106. 106 Sun, H., Schlondorff, J., Higgs, H.N., et al. Inverted formin 2 regulates actin dynamics by antagonizing Rho/diaphanous-related formin signaling. J Am Soc Nephrol 24 (2013), 917–929.
107. 107 Banas, M.C., Banas, B., Hudkins, K.L., et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol 19 (2008), 704–713.
108. 108 Delville, M., Sigdel, T.K., Wei, C., et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med, 6, 2014, 256ra136.
109. 109 Forst, A.L., Olteanu, V.S., Mollet, G., et al. Podocyte purinergic P2X4 channels are mechanotransducers that mediate cytoskeletal disorganization. J Am Soc Nephrol 27 (2015), 848–862.
110. 110 George, B., Vollenbroker, B., Saleem, M.A., et al. GSK3beta inactivation in podocytes results in decreased phosphorylation of p70S6K accompanied by cytoskeletal rearrangements and inhibited motility. Am J Physiol Renal Physiol 300 (2011), F1152–F1162.
111. 111 Godel, M., Hartleben, B., Herbach, N., et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121 (2011), 2197–2209.
112. 112 Kawakami, T., Gomez, I.G., Ren, S., et al. Deficient autophagy results in mitochondrial dysfunction and FSGS. J Am Soc Nephrol 26 (2015), 1040–1052.
113. 113 Kimura, J., Ichii, O., Miyazono, K., et al. Overexpression of Toll-like receptor 8 correlates with the progression of podocyte injury in murine autoimmune glomerulonephritis. Sci Rep, 4, 2014, 7290.
114. 114 Ma, H., Togawa, A., Soda, K., et al. Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J Am Soc Nephrol 21 (2010), 1145–1156.
115. 115 Naves, M.A., Requiao-Moura, L.R., Soares, M.F., et al. Podocyte Wnt/ss-catenin pathway is activated by integrin-linked kinase in clinical and experimental focal segmental glomerulosclerosis. J Nephrol 25 (2012), 401–409.
116. 116 Niranjan, T., Bielesz, B., Gruenwald, A., et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 14 (2008), 290–298.
117. 117 Wang, L., Ellis, M.J., Fields, T.A., et al. Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis. Kidney Blood Press Res 31 (2008), 111–121.
118. 118 Lindskog, A., Ebefors, K., Johansson, M.E., et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 21 (2010), 1290–1298.
119. 119 Koshikawa, M., Mukoyama, M., Mori, K., et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16 (2005), 2690–2701.
120. 120 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.